Differentiating COVID-associated myocarditis from other Diseases: Difference between revisions
Jump to navigation
Jump to search
Line 53: | Line 53: | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" |- | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔(Low-grade) | ||
| style="background: #F5F5F5; padding: 5px;" |✔/- | | style="background: #F5F5F5; padding: 5px;" |✔/- | ||
| style="background: #F5F5F5; padding: 5px;" |✔/- | | style="background: #F5F5F5; padding: 5px;" |✔/- | ||
Line 153: | Line 153: | ||
|style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-19-associated pulmonary embolism]] | |style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-19-associated pulmonary embolism]] | ||
| style="background: #F5F5F5; padding: 5px;" |✔ (Usually sudden-onset) | | style="background: #F5F5F5; padding: 5px;" |✔ (Usually sudden-onset) | ||
| style="background: #F5F5F5; padding: 5px;" |✔ ([[ | | style="background: #F5F5F5; padding: 5px;" |✔ ([[Pleuritic]]) | ||
| style="background: #F5F5F5; padding: 5px;" |✔ (If massive PE) | | style="background: #F5F5F5; padding: 5px;" |✔ (If massive PE) | ||
| style="background: #F5F5F5; padding: 5px;" |✔ (Low-grade) | | style="background: #F5F5F5; padding: 5px;" |✔ (Low-grade) |
Latest revision as of 08:47, 24 July 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mounika Reddy Vadiyala, M.B.B.S.[2]
Overview
COVID-19-associated myocarditis must be differentiated from other causes of dyspnea and chest pain, elevated cardiac biomarkers, ventricular dysfunction such as including Acute Coronary Syndrome, Stress-induced cardiomyopathy (Takotsubo cardiomyopathy) and Heart failure.
Differential Diagnosis
COVID-19-associated myocarditis must be differentiated from other causes of dyspnea and chest pain, elevated cardiac biomarkers, ventricular dysfunction such as including acute coronary syndrome, stress-induced cardiomyopathy (takotsubo cardiomyopathy) and heart failure.
Diseases | Symptoms | Physical Examination | Diagnostic tests | Other Findings | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Dyspnea on Exertion | Chest Pain | Hemoptysis | Fever | Tachypnea | Tachycardia | Chest X-ray | ECG | Echocardiography | CT scan and CMR | ||
COVID-19-associated myocarditis | ✔ | ✔ | - | ✔ | ✔ | ✔ |
|
|
|
|
Increased cardiac troponin level |
COVID-19-associated myocardial infarction | ✔ | ✔ | - | ✔(Low-grade) | ✔/- | ✔/- |
|
|
|
- |
Increased cardiac troponin levels |
COVID-19-associated stress cardiomyopathy | ✔ | ✔ | - | - | ✔ | ✔ |
|
|
|
|
Increased cardiac troponin and pro-BNP level, transient increase in catecholamine levels. |
COVID-19-associated heart failure | ✔ | - | ✔ | - | ✔ | ✔ |
|
|
|
|
Increased NT-proBNP and cardiac troponins levels |
COVID-19-associated pneumonia | ✔ | ✔ (Pleuritic) | ✔ | ✔ (Usually high) | ✔ | ✔ |
|
- | Increased inflammatory markers, including ESR, hs-CRP | ||
COVID-19-associated acute respiratory distress syndrome | ✔ | - | ✔ | ✔ | ✔ | ✔ |
|
- |
|
- | |
COVID-19-associated pulmonary embolism | ✔ (Usually sudden-onset) | ✔ (Pleuritic) | ✔ (If massive PE) | ✔ (Low-grade) | ✔ | ✔ |
|
|
|
|